Abstract
Given the past two decades of over 40 failed trials of amyloid-lowering therapies in Alzheimer’s Disease (AD), many of which succeeded in lowering amyloid as designed, we present an ethical argument for emptying the drug pipeline of tests of amyloid-lowering agents so as to end the historical dominance of the amyloid-reducing therapeutic approach in AD.
| Original language | English |
|---|---|
| Pages (from-to) | 80-81 |
| Number of pages | 2 |
| Journal | AJOB Neuroscience |
| Volume | 15 |
| Issue number | 2 |
| DOIs |
|
| Publication status | Published - 2024 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2022 Taylor & Francis Group, LLC.
Keywords
- Alzheimer’s disease
- clinical ethics
- clinical trials
- dementia
- equipoise
- research ethics